Mycosis fungoides diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
| Line 71: | Line 71: | ||
| colspan="3" |3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | | colspan="3" |3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:15, 12 February 2019
|
Mycosis fungoides Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mycosis fungoides diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mycosis fungoides diagnostic study of choice |
|
Risk calculators and risk factors for Mycosis fungoides diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Mycosis fungoides is primarily diagnosed based on the clinical presentation.
Diagnostic Study of Choice
- Mycosi fungoides must be performed when:[1]
- The patient presents with symptomatic progressive skin lesions such as: patches, plaques, tumors, and erytheroderma, and a poorer prognosis in later stages.
- There is no single diagnostic study of choice for the diagnosis of mycosis fungoides, and mycosis fungoides can be diagnosed difficult by nonspecific skin presentation.
- Lesions disease present with skin lesions not treated by useual medication.
- Mycosis fungoides is primarily diagnosed based on the clinical presentation.
| Criteria | Major( 2pinots) | Minor(1point) |
|---|---|---|
| Persistent and/or progressive patches and plaques plus | Any 2 | Any 1 |
| Clinical | ||
| 1. Non–sun-exposed location | ||
| 2.Size/shape variation | ||
| 3.Poikiloderma | ||
| Histopathologic | ||
| Superficial lymphoid infiltrate plus | Both | Either |
| 1. Epidermotropism | ||
| 2. Atypia | ||
| Molecular/biological | ||
| Clonal TCR gene rearrangement | Present | |
| Immunopathologic | ||
| 1. CD2, CD3, CD5 in <59% of T cells | Any 1 | |
| 2. CD7 in <10% of T cells | ||
| 3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells | ||
References
- ↑ Galper SL, Smith BD, Wilson LD (May 2010). "Diagnosis and management of mycosis fungoides". Oncology (Williston Park, N.Y.). 24 (6): 491–501. PMID 20568590.
- ↑
- ↑ Pimpinelli, Nicola; Olsen, Elise A.; Santucci, Marco; Vonderheid, Eric; Haeffner, Andreas C.; Stevens, Seth; Burg, Guenter; Cerroni, Lorenzo; Dreno, Brigitte; Glusac, Earl; Guitart, Joan; Heald, Peter W.; Kempf, Werner; Knobler, Robert; Lessin, Stuart; Sander, Christian; Smoller, Bruce S.; Telang, Gladys; Whittaker, Sean; Iwatsuki, Keiji; Obitz, Erik; Takigawa, Masahiro; Turner, Maria L.; Wood, Gary S. (2005). "Defining early mycosis fungoides". Journal of the American Academy of Dermatology. 53 (6): 1053–1063. doi:10.1016/j.jaad.2005.08.057. ISSN 0190-9622.